Theralase Technologies Inc. announced that Ashish M. Kamat has agreed to join the Theralase Medical and Scientific Advisory Board. Dr. Kamat is an internationally recognized expert in urologic oncology and an authority in the management of urologic cancers.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.21 CAD | +10.53% |
|
+13.51% | +20.00% |
06-20 | Theralase Technologies Inc. Announces Rutherrin Repurposes Non-Cancer Drugs for Cancer Therapy | CI |
06-12 | Theralase Technologies Inc. Announces Rutherrin Increases Efficacy of Chemotherapy | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+20.00% | 36.72M | |
-4.26% | 810M | |
-31.56% | 216M | |
-.--% | 121M | |
-26.78% | 84.74M | |
+0.51% | 55.64M |
- Stock Market
- Equities
- TLT Stock
- News Theralase Technologies Inc.
- Ashish M. Kamat Joins Theralase Technologies Inc.'s Medical and Scientific Advisory Board